noctuRNA Therapeutics
About noctuRNA Therapeutics
NoctuRNA Therapeutics develops circular RNA-based therapies that target structural RNA elements critical to the progression of various diseases, including infectious and neuromuscular disorders. Their approach combines these therapies with advanced delivery techniques to address currently incurable conditions.
```xml <problem> Many diseases, including infectious and neuromuscular disorders, progress due to structural RNA elements. Addressing these elements with traditional methods is challenging, leaving many conditions incurable. </problem> <solution> NoctuRNA Therapeutics develops circular RNA-based therapies specifically designed to target the structural RNA elements that drive disease progression. By combining these targeted therapies with advanced delivery techniques, NoctuRNA aims to effectively address and treat diseases that are currently considered intractable. This approach offers a novel way to intervene in disease pathways by directly targeting the root cause at the RNA level. </solution> <features> - Circular RNA-based therapeutics targeting structural RNA elements. - Advanced delivery techniques for effective therapeutic delivery. - Applicability to a wide range of pathologies, including infectious diseases and neuromuscular disorders. </features> <target_audience> The primary target audience includes patients suffering from infectious and neuromuscular disorders, as well as researchers and clinicians seeking novel therapeutic approaches for these conditions. </target_audience> ```
What does noctuRNA Therapeutics do?
NoctuRNA Therapeutics develops circular RNA-based therapies that target structural RNA elements critical to the progression of various diseases, including infectious and neuromuscular disorders. Their approach combines these therapies with advanced delivery techniques to address currently incurable conditions.
Where is noctuRNA Therapeutics located?
noctuRNA Therapeutics is based in Barcelona, Spain.
When was noctuRNA Therapeutics founded?
noctuRNA Therapeutics was founded in 2022.
How much funding has noctuRNA Therapeutics raised?
noctuRNA Therapeutics has raised $711.9K.
Who founded noctuRNA Therapeutics?
noctuRNA Therapeutics was founded by Marc Talló Parra and Miriam Corredor Sánchez.
- Marc Talló Parra - Co-founder and CSO of noctuRNA Therapeutics
- Miriam Corredor Sánchez - CEO
- Location
- Barcelona, Spain
- Founded
- 2022
- Funding
- $711.9K
- Employees
- 5 employees